Down Syndrome and Alzheimer's Disease
Chair: Elliott Mufson
Individuals with Down syndrome develop Alzheimer's disease (AD) neuropathology with near conformity in their 4th to 5th decade, and are at a much higher risk of developing AD dementia than the general population. Not all research sites have access to DS individuals between the ages of 25 and 40; the years when most likely AD neuropathology develops. Further, DS is a fairly uncommon genetic abnormality, with approximately one in every 700 births; this means that a multi-site collaborative team in terms of clinical trials and neuropathology repositories is more likely to yield breakthrough results than individual efforts. The intention of the Down syndrome and Alzheimer's disease (DS-AD) PIA is to meet two times per year as a group, in order to form a national tissue repository, and also to set up a data sharing network and work with industry to develop treatment targets and biomarkers for DS-AD.
On Twitter? Follow @ISTAART and use #DSADPIA to share PIA news and stay up to date on PIA activity.
Please log in to access expanded content for members.
- Alliance of Women Alzheimer's Researchers (AWARE)
- Atypical Alzheimer's disease and Associated Syndromes
- Biofluid Based Biomarkers
- Clinical Trials Advancement and Methods
- Design and Data Analytics
- Diversity and Disparities
- Down Syndrome and Alzheimer's Disease
- Immunity and Neurodegeneration
- Neuropsychiatric Syndromes
- Non-pharmacological Interventions
- Nutrition, Metabolism, and Dementia
- Perioperative Cognition and Delirium
- Reserve, Resilience and Protective Factors
- Subjective Cognitive Decline
- Vascular Cognitive Disorders
- Join ISTAART. Gain PIA Access.